Advanced Enzyme Share Price

Advanced Enzyme Technologies Limited, together with its subsidiaries, is a leading Indian research-driven biotechnology company engaged in the research, development, manufacture, and marketing of enzymes and probiotics in India and internationally. The company offers enzyme-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing. It also provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids.

The Advanced Enzyme Technologies share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Advanced Enzyme Technologies stock price often mirrors shifts in demand from food processing, pharmaceuticals, and animal nutrition sectors, and investor views on the biotechnology sector’s growth prospects. Factors such as the pace of new product introductions, competitive intensity, raw material cost inflation, and changing regulatory frameworks influence near-term market valuation and medium-term earnings forecasts.All these factors must be closely monitored to have an idea about the Advanced Enzyme Technologies stock price movements.

Advanced Enzyme Technologies live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Advanced Enzyme Technologies live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Advanced Enzyme Technologies share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook

Advanced Enzyme Technologies Limited Company Fundamentals

a. Company Background

Advanced Enzyme Technologies Limited is an Indian biotechnology company engaged in the research, development, manufacture, and marketing of enzymes and probiotics for human healthcare, animal nutrition, food processing, and non-food applications. The company traces its origins to 1957, when founder Late L. C. Rathi pioneered the extraction of papain, an enzyme complex derived from papaya fruit. The company was formally incorporated on March 15, 1989 under the Companies Act, 1956, as ‘Advanced Biochemicals Private Limited‘ in Maharashtra. The company was converted into a public company and renamed Advanced Biochemicals Limited on May 28, 1992, and subsequently changed its name to Advanced Enzyme Technologies Limited in 2005. The company has its registered office in Thane, Maharashtra, India, with corporate office at Sun Magnetica, Thane. Advanced Enzyme Technologies is the largest enzyme company in India and one of the few in the world with capabilities across the entire enzyme value chain from discovery to commercial production. The company has manufacturing facilities at Sinnar and Pitampur SEZ near Indore, and has expanded globally through acquisitions of Cal India Foods International in the US in 2011 and evoxx technologies GmbH in Germany in 2017. It operates within India‘s growing biotechnology and specialty chemicals industry, driven by increasing demand for sustainable and enzyme-based solutions across food, pharma, and industrial sectors.

b. Product Lines

• Human nutrition enzymes and probiotics (digestive enzymes, nutritional supplements, gut health products)

• Animal nutrition enzymes (feed enzymes for livestock, poultry, and aquaculture)

• Food processing enzymes (for baking, brewing, fruit and vegetable processing, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, oils and fats processing)

• Non-food processing enzymes (for textile, leather, pulp and paper processing, detergents and cleaning aids)

• Biofuel enzymes (for bioethanol and biodiesel production)

• Biocatalysis enzymes for pharmaceutical synthesis

• Specialty enzymes for industrial applications

c. Company Revenue Model

• Primary revenue from the Human Nutrition segment, including enzyme-based nutritional supplements and probiotics

• Revenue from the Animal Nutrition segment through sale of feed enzymes

• Revenue from the Food Processing segment for industrial enzyme applications in baking, brewing, and food manufacturing

• Revenue from the Non-Food Processing segment including enzymes for textiles, detergents, and pulp and paper

• Revenue from contract manufacturing and toll manufacturing services

• Revenue from exports of enzymes and probiotics to international markets across Europe, the United States, Asia, and other regions

d. Geographic Presence

• Registered office and corporate headquarters located in Thane, Maharashtra, India

• Manufacturing facilities at Sinnar, Nashik district, and Pitampur SEZ near Indore, Madhya Pradesh

• International presence with step-down subsidiaries in the United States (Cal India Foods International and Advanced Supplementary Technologies Corporation), Germany (evoxx technologies GmbH), and China (Advanced Enzyme Far East Ltd.)

• Products marketed and sold across India, Europe, the United States, Asia, and internationally

• Delivery model leverages in-house R&D and manufacturing capabilities across multiple geographies

e. Key Milestones

• 1957: Founder L. C. Rathi pioneered papain extraction, marking the beginning of the journey

• 1989: Incorporated as Advanced Biochemicals Private Limited on March 15, 1989

• 1992: Converted to a public company and renamed Advanced Biochemicals Limited on May 28, 1992

• 2004: Ranked as the largest domestic manufacturer of industrial enzymes in India

• 2005: Name changed to Advanced Enzyme Technologies Limited

• 2011: Acquired Cal India Foods International, establishing direct presence in the US market

• 2012: Acquired Advanced Supplementary Technologies Corporation, consolidating US presence

• 2016: Initial Public Offering (IPO) opened on July 20, 2016, with issue price of ₹896 per share; shares listed on NSE and BSE on August 1, 2016 at ₹1,210

• 2016: Acquired majority stake in JC Biotech Private Limited (70% of paid-up share capital)

• 2017: Stock split from face value of ₹10 to face value of ₹2 effective May 26, 2017

• 2017: Acquired 100% stake in evoxx technologies GmbH, a German company

• 2021: Acquired 100% stake in SciTech Specialties Private Limited

f. Industry Perspective: Enzymes and Biotechnology Industry in India

Advanced Enzyme Technologies operates in the global and Indian enzymes and biotechnology industry. Globally, the enzymes market continues to expand driven by increasing demand for sustainable and bio-based solutions across food, feed, pharma, and industrial sectors. In India, the enzymes market has witnessed substantial growth. The India enzymes market generated revenue of USD 481.4 million in 2025 and is expected to reach USD 892.8 million by 2033, growing at a CAGR of 8.1% from 2026 to 2033. The India enzymes market size reached USD 500.1 million in 2025 and is expected to reach USD 952.5 million by 2034, exhibiting a growth rate (CAGR) of 7.42% during 2026-2034. Industrial enzymes was the largest revenue-generating type in 2025, while specialty enzymes is the fastest-growing segment. The India industrial enzymes market was valued at USD 0.25 billion in 2024 and is anticipated to reach USD 0.35 billion by 2030, with a CAGR of 5.95% during the forecast period. Key growth drivers include increasing demand for processed foods, growing awareness of digestive health and nutritional supplements, rising adoption of enzyme-based solutions in animal feed to improve livestock productivity, and the shift towards sustainable manufacturing processes. The industry faces challenges including raw material price volatility, competition from global players such as Novozymes and DuPont, and regulatory compliance costs. However, the industry outlook remains positive, supported by increasing healthcare awareness, expanding food processing sector, and government initiatives promoting biotechnology and industrial enzymes.

Advanced Enzyme Technologies Limited Stock Market Presence: Listings & Index Representation

Advanced Enzyme Technologies Limited is actively traded on India‘s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol ADVENZYMES and on the Bombay Stock Exchange (BSE) with the scrip code 540025. The ISIN number of the company’s equity shares is INE837H01020. The face value of the equity shares is ₹2 per share. Its listing on both exchanges ensures that the Advanced Enzyme Technologies price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Advanced Enzyme Technologies is included in indices such as the BSE 500, BSE AllCap, BSE SmallCap, BSE Healthcare, and Nifty Smallcap 250. These index participations signal the company‘s relevance within market categories that attract both active and passive investment flows. Being represented in multiple indices enhances the visibility and liquidity of the Advanced Enzyme Technologies stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India‘s biotechnology and specialty chemicals landscape. The inclusion of Advanced Enzyme Technologies in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Advanced Enzyme Technologies Limited Stock Performance and Share Price History

The Advanced Enzyme Technologies price has displayed significant volatility over the past decade, shaped by the company‘s financial performance, biotechnology sector cycles, and broader market trends. The Advanced Enzyme Technologies share price delivered a strong positive return of 103.5% in calendar year 2020, reflecting robust recovery and strong demand for enzyme-based products. The Advanced Enzyme Technologies share price also delivered positive returns of 33.7% in 2023. However, the Advanced Enzyme Technologies share price experienced negative returns of 13.8% in 2025, 6.8% in 2024, 13.9% in 2022, 3.1% in 2021, and 5.9% in 2019. Over the 5-year period ending January 2026, the Advanced Enzyme Technologies share price has delivered a cumulative return of approximately -13.1%, underperforming the BSE Commodities index which delivered 14.7% and the BSE Small Cap index which delivered 8.0% over the same period. The Advanced Enzyme Technologies share price reached a 52-week high of ₹366.25 and a 52-week low of ₹251.95, indicating a wide trading range and substantial price fluctuations. As of April 2026, the Advanced Enzyme Technologies share price was trading at approximately ₹268.40-₹281.40 on the NSE, with a market capitalisation of approximately ₹3,010-₹3,250 crore.

The Advanced Enzyme Technologies stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 18.54% year-on-year rise in consolidated net profit for the June 2024 quarter, the Advanced Enzyme Technologies stock price showed a positive reaction. The Advanced Enzyme Technologies share price has shown a pattern of positive momentum following strong earnings reports, while periods of weak financial results or market consolidation have contributed to declines in the Advanced Enzyme Technologies stock price. The Advanced Enzyme Technologies share price delivered a 1-year total return of approximately 7.84% (price only) as of April 2026, or 9.64% including dividends, underperforming the Pharmaceuticals & Biotechnology industry which returned 6.49% over the same period. The Advanced Enzyme Technologies share price has shown a YTD return of approximately -11.2% as of January 2026, while the 1-month return was -12.9%, the 3-month return was -14.6%, and the 1-year return was -20.1%. The Advanced Enzyme Technologies share price has been influenced by corporate developments including the IPO in 2016, the stock split from face value of ₹10 to ₹2 in 2017, acquisitions of JC Biotech, Cal India Foods International, evoxx technologies GmbH, and SciTech Specialties, and consistent dividend payments. The Advanced Enzyme Technologies share price has shown average weekly volatility of approximately 7% over the past year, which has been stable and in line with the biotechnology industry. Based on data, the beta for Advanced Enzyme Technologies has been recorded at 1.13 for the long-term range, indicating that the stock has exhibited higher volatility than the broader market over extended periods. The Advanced Enzyme Technologies share price has a 10-year aggregate net profit of ₹1,162.08 crore and a 10-year aggregate EBITDA of ₹1,831.76 crore. Comprehending these patterns in the Advanced Enzyme Technologies share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Advanced Enzyme Technologies stock price movements illustrate how industry fundamentals, demand cycles, raw material cost pressures, and investor expectations converge in market pricing.

Advanced Enzyme Technologies Limited Investor Relevance and Role in Portfolio

Advanced Enzyme Technologies holds a distinctive position for portfolio investors who seek exposure to the Indian biotechnology and specialty chemicals sector with a focus on enzymes and probiotics. The company‘s diversified product portfolio across human nutrition, animal nutrition, food processing, and non-food applications aligns it with investment strategies that value both domestic consumption growth and global export opportunities. The Advanced Enzyme Technologies share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor healthcare spending indicators and food processing sector growth when evaluating allocation decisions.

Institutional stakeholders play a significant role in Advanced Enzyme Technologies’ ownership profile. The promoters held 43.04% of the company as of December 2025, showing a stable trend with a marginal decrease from 43.07% in the previous quarter. Mutual fund holders of Advanced Enzyme Technologies include UTI Mutual Fund and other institutional investors. Mutual funds collectively hold 2.16% of the company. Foreign Institutional Investors (FIIs) hold 25.86% of the company, showing an increase from 25.41% in the previous quarter. Domestic Institutional Investors (DIIs) hold 3.35% of the company. Retail and other shareholders hold 25.59% of the company. Overall institutional holding in the company stands at approximately 31.36% as of December 2025, with the number of FII investors increasing from 87 to 91 during the quarter.

Based on data, the beta for Advanced Enzyme Technologies has been recorded at 1.13 for the long-term range, indicating that the stock has exhibited higher volatility than the broader market over extended periods. In the short-term daily analysis, beta values of 1.18 for the one-month range and 1.42 for the three-month range show high sensitivity to market fluctuations. Weekly data reveals a beta of 0.839 over one year and 1.12 over two years, indicating a rise in volatility over longer durations. The 2-week beta over a two-year period stands at 1.21, reflecting high responsiveness, while the monthly beta over two years reaches 1.08. The mean values across these periods range from 278.52 to 347.25, with standard deviations from 2.47 to 9.44, indicating higher price variability in longer periods. Other sources report a beta of 0.6885 as the sector average, with Advanced Enzyme Technologies showing varying beta depending on the time frame. The Advanced Enzyme Technologies share price has shown periods of heightened responsiveness to sector-specific news, quarterly earnings releases, and raw material price movements. The Advanced Enzyme Technologies share price reflects that the company‘s position in the biotechnology sector may result in moderate to high price fluctuations. The Advanced Enzyme Technologies stock price is thus viewed as a growth opportunity within a portfolio context with varying volatility characteristics depending on the time frame.

Advanced Enzyme Technologies Limited Sectoral Relevance and Peer Positioning

The sector relevance of Advanced Enzyme Technologies is anchored in its role within the broader Indian biotechnology and specialty chemicals industry, where it competes with other diversified pharmaceutical and biotechnology companies. As part of this industry, the company’s strategic positioning connects human nutrition enzymes, animal nutrition enzymes, food processing enzymes, and non-food processing enzymes that serve multiple end-user segments. Competitors in adjacent segments include companies such as Novozymes (Denmark), DuPont Industrial Biosciences (USA), BASF SE (Germany), DSM-Firmenich (Netherlands), Amano Enzyme Inc. (Japan), and Codexis Inc. (USA). In the domestic listed space, competitors include Aarey Drugs & Pharmaceuticals Ltd., Aarti Drugs Ltd., Aarti Pharmalabs Ltd., Abbott India Ltd., and Accent Microcell Ltd. Larger global players such as Novozymes and DuPont have larger scale and global footprints, though Advanced Enzyme Technologies competes directly in the Indian enzyme market. Firms with parallels in either R&D capabilities or product complexity are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Advanced Enzyme Technologies P/E ratio tend to reflect narrative shifts in earnings expectations and investor confidence relative to these peers. The Advanced Enzyme Technologies P/E ratio stood at approximately 20.4-26.93 as of April 2026, compared to the industry P/E of 33.98, indicating that the stock is trading at a discount to the industry average. The Advanced Enzyme Technologies earnings history over the past decade has shown a pattern of consistent growth with recent moderation. Revenue increased from ₹510.69 crore in FY2021 to ₹669.95 crore in FY2025, representing a growth of approximately 31% over five years. Net profit increased from ₹151.46 crore in FY2021 to ₹133.97 crore in FY2025, showing a decline of approximately 12% over the same period. For TTM ended December 2025, net profit stood at approximately ₹147 crore. The 10-year aggregate net profit of the company stands at approximately ₹1,162.08 crore. Quarterly net profit for the quarter ended December 2025 showed moderate performance. The Advanced Enzyme Technologies EPS narrative has followed a similar pattern of growth. EPS (TTM) has been recorded at approximately ₹11.01-₹13.60 over different periods, with a current TTM EPS of approximately ₹13.2. Basic EPS for FY2025 stood at ₹11.97 compared to ₹12.24 in FY2024. The Advanced Enzyme Technologies market cap has shown a pattern of fluctuation over the past decade. Advanced Enzyme Technologies market cap increased from approximately ₹3,000 crore in earlier years to approximately ₹3,250 crore as of April 2026. This directional behaviour in valuation multiples demonstrates how market expectations around growth prospects and earnings durability influence broader assessment of the Advanced Enzyme Technologies share price within its industry context. The Advanced Enzyme Technologies stock price remains a key barometer for the enzyme biotechnology segment.

Over the last ten years, Advanced Enzyme Technologies market cap has shown a pattern of significant growth followed by moderation. The company’s market cap increased from lower levels at the time of IPO in 2016 to approximately ₹3,250 crore as of April 2026. The market cap has shown a 10-year aggregate net profit of approximately ₹1,162.08 crore, a 10-year aggregate EBITDA of approximately ₹1,831.76 crore, and a 10-year aggregate CFO of approximately ₹1,295.68 crore. The current market cap stands at approximately ₹3,250 crore, having ranged between ₹2,857 crore and ₹3,267 crore over recent periods.

Advanced Enzyme Technologies earnings, in terms of net profit, have exhibited a pattern of growth followed by recent moderation. Net profit increased from ₹151.46 crore in FY2021 to ₹123.80 crore in FY2022, to ₹103.87 crore in FY2023, to ₹136.95 crore in FY2024, and to ₹133.97 crore in FY2025. Revenue increased from ₹510.69 crore in FY2021 to ₹535.80 crore in FY2022, to ₹566.09 crore in FY2023, to ₹660.53 crore in FY2024, and to ₹669.95 crore in FY2025. The 10-year aggregate net profit of the company stands at approximately ₹1,162.08 crore. Quarterly net profit for the June 2024 quarter rose 18.54% year-on-year, indicating recent improvement.

Advanced Enzyme Technologies EPS history over the past decade has shown a pattern of fluctuation. EPS (TTM) has been recorded at approximately ₹11.01-₹13.60 over different periods, with a current TTM EPS of approximately ₹13.2. Basic EPS stood at ₹11.97 in FY2025 compared to ₹12.24 in FY2024, ₹9.28 in FY2023, ₹11.06 in FY2022, and ₹13.53 in FY2021. This volatile EPS trajectory reflects the impact of raw material price fluctuations, competitive intensity, and the cyclical nature of the biotechnology industry.

Advanced Enzyme Technologies P/E ratio history has shown a pattern of variation, fluctuating between moderate and elevated levels over the past decade. The P/E ratio stood at approximately 20.4-26.93 as of April 2026, compared to the industry P/E of 33.98. The P/E ratio has ranged from approximately 19.55 to 30.48 over different periods. This valuation discount reflects that investor expectations remain anchored to the company‘s earnings growth trajectory and market position in the enzyme biotechnology segment.

Summary

Advanced Enzyme Technologies is a leading Indian biotechnology company listed on both the NSE and BSE, where the Advanced Enzyme Technologies share price reflects biotechnology demand cycles, healthcare spending trends, and competitive dynamics within the specialty chemicals sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader health and wellness consumption patterns. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in the Indian enzyme biotechnology market.